Lorfast MT Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, which play a key role in the inflammatory process associated with asthma and allergic rhinitis. The synergistic action of these two agents provides comprehensive relief from both immediate hypersensitivity symptoms and the underlying inflammatory response. Lorfast MT is particularly useful in patients who require both antihistaminic and anti-inflammatory effects for optimal symptom control. It is generally well tolerated, with a low incidence of adverse effects such as headache, fatigue, or gastrointestinal discomfort. The tablet should be administered orally once daily, preferably in the evening, with or without food, as directed by a healthcare professional. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with known hypersensitivity to either component. Regular monitoring and adherence to prescribed dosage enhance therapeutic outcomes and minimize potential risks.